Effectiveness of hyperbaric oxygen therapy for virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation

Kohei Hosokawa 1 · Go Aoki 1,2 · Kinya Ohata 1 · Hiroyuki Takamatsu 1 · Noriharu Nakagawa 1 · Tatsuya Imi 1 · Noriko Iwaki 1 · Kiyoko Ito 3 · Mitsuhiro Kawano 2 · Takashi Nakamura 4 · Masato Takamori 3 · Ken Ishiyama 1 · Yukio Kondo 1 · Hirohito Yamazaki 1 · Shinji Nakao 1

Received: 20 October 2020 / Revised: 2 March 2021 / Accepted: 4 March 2021 / Published online: 16 March 2021
© Japanese Society of Hematology 2021

Abstract
Although some studies have suggested the effectiveness of hyperbaric oxygen (HBO) therapy for hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT), the role of HBO has not been established. We compared the treatment outcomes of 8 patients with viral HC (adenovirus [ADV], n = 2; BK virus [BKV], n = 6) treated with HBO (HBO[+]) and 8 patients (ADV, n = 2; BKV, n = 6) treated with conventional therapy (HBO[−]), such as urinary catheterization and intravenous cidofovir. HBO therapy was performed at 2.1 atmospheres for 90 min/day until clinical improvement was achieved. The median number of HBO treatments was 10 (range 8–12). The median duration of HBO treatment was 19.5 days (range 10–23 days). All 8 HBO(+) patients achieved complete remission (CR) at a median of 14.5 days (range 5–25 days). Of the 8 HBO(−) patients, 5 (62.5%) obtained CR and 3 remained symptomatic for 2–6 months. The cumulative incidence of transplant-related mortality at day 100 after allogeneic HSCT was significantly higher in the HBO(−) patients than in the HBO(+) patients (14.2 vs. 0%, P < 0.05). No severe HBO-related adverse effects were observed. In conclusion, HBO is a feasible option for treating viral HC after allogeneic HSCT.

Keywords Hyperbaric oxygen therapy · Hemorrhagic cystitis

Introduction
Hemorrhagic cystitis (HC) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). HC occurs in 8.6–24% of allo-HSCT recipients and severely impairs their quality of life [1–6]. Early-onset HC, which occurs within 1 week after HSCT, mostly develops due to the regimen-related toxicity, while late-onset HC after engraftment is usually caused by viruses, such as human polyomavirus BK (BKV), polyomavirus JC, adenovirus (ADV), and cytomegalovirus (CMV). A number of retrospective studies have identified various risk factors for HC after allo-HSCT. These included busulfan (BU)-containing conditioning regimens, unrelated donor, the occurrence of graft-versus-host disease (GVHD), and CMV reactivation [6–9].

Supportive therapies, including forced diuresis, hydration, continuous bladder irrigation, and platelet transfusion, have been the standard of care for HC. Several retrospective studies have reported the efficacy of cidofovir
(CDV) for BKV-associated HC (BKV-HC) and ADV-associated HC (ADV-HC) after allo-HSCT [10–16]. However, its therapeutic efficacy for CDV has not been comprehensively validated by prospective controlled studies, and the optimal dose remains unclear. In addition, the use of CDV may exacerbate the renal dysfunction that is often associated with HC. The successful intravesical instillation of CDV has been reported, but their clinical efficacy is limited [17].

Hyperbaric oxygen (HBO) therapy is commonly used for the treatment of arterial gas embolism, poorly healing diabetic wounds, osteomyelitis, radiation tissue injury, and carbon monoxide poisoning, and is known to be safe, non-invasive, and cost-effective. HBO has also been shown to ameliorate radiation-induced HC by promoting fibroblast proliferation and capillary angiogenesis, decreasing edema, and facilitating regeneration of the damaged hypoxic urothelium [18, 19]. Recent studies indicated the clinical effectiveness of HBO therapy for BKV-HC after allo-HSCT [20–23]. Savva-Bordalo et al. presented 16 patients with HC after allo-HSCT who underwent HBO therapy, and who showed a high response rate (94%). However, few studies have compared the clinical effectiveness of HBO therapy with that of conventional therapy in the treatment of HC after allo-HSCT. In the present study, we analyzed the efficacy and safety of HBO therapy in comparison to conventional therapy for patients with post-HSCT viral HC who were managed in our institution.

Patients and methods

Patients

Among the patients who underwent allo-HSCT at our institution between May 2007 and August 2017, 22 patients developed virus-associated HC and 16 patients without grade II–IV acute GVHD (aGVHD) were included in the study. Their medical records were retrospectively analyzed. Eight of the 16 patients (50%) were treated with HBO therapy [HBO(+)], while 8 patients (50%) who received conventional therapies, such as intravenous hydration with forced diuresis, urinary catheter, and intravenous CDV [HBO(−)]. The selected treatments for viral HC were based on the judgment of each individual physician. The clinical characteristics of the patients, including the original diseases, clinical statuses, conditioning regimens, sources of allo-HSCT, and GVHD prophylaxis regimens are shown in Table 1. The median age of the HBO(+) patients was 51.5 years (range 32–64 years). Antithymocyte globulin (ATG) was administered to 2 (UPNs 3 and 15) of 16 cases as prophylaxis against GVHD. Four (UPNs 3–6) of 8 HBO(+) cases were grafted with peripheral blood stem cells (PBSCs) from an HLA-haploidentical donor; three (UPNs 4–6) received PBSCs from HLA-haploidentical donors using post-transplant high-dose cyclophosphamide. The 16 patients received 2–12 (median 12) Gy of total body irradiation. There was no significant difference in the age, original disease, performance status, hematopoietic cell transplant-comorbidity index (HCT-CI), conditioning regimen, or stem cell source between the HBO(+) patients and the HBO(−) patients.

All patients provided their informed consent in accordance with the Declaration of Helsinki. This retrospective analysis was approved by the ethics committee of the Kanazawa University Hospital (No. 2453).

Definitions

Engraftment was defined as a neutrophil count of > 0.5 × 10⁹/L for three consecutive days. HC was diagnosed when microscopic (blood in urine grade ≥ 1+) or macroscopic hematuria accompanied by dysuria, pollakisuria, urinary urgency, and/or the sensation of residual urine, which developed without evidence of bacteriuria [24]. BKV- or ADV-HC was diagnosed when a qualitative PCR assay detected BKV or ADV in the urine of symptomatic patients. The date of onset of HC was defined as the first day on which the patient complained of urinary symptoms. The severity of hematuria was graded according to the criteria for adverse effects [25]. Transplant-related mortality (TRM) was defined as death due to any transplantation-related causes, other than disease relapse.

HBO therapy

HBO therapy was started at 2.1 atmospheres for 90 min per day from the day on which the patient showed grade II–III symptoms of HC, and therapy was continued until the patient achieved clinical improvement, which was defined as complete resolution (CR) or partial resolution (PR) of macroscopic hematuria and urinary symptoms, such as pain on urination. CR of HC was defined as undetectable blood in urine (|−| or |±| for hemoglobin) and the disappearance of dysuria, pollakisuria, urinary urgency, and the sensation of residual urine related to HC.

Statistical analysis

Fisher’s exact test was used for the analysis of categorical variables and the Mann–Whitney’s U test was used for the analysis of continuous variables. The Wilcoxon signed-rank test was used for paired samples. The probabilities of TRM were estimated based on the cumulative incidence method to compensate for any competing risks, and the groups were then compared using Gray’s test. P values of < 0.05 were considered to indicate statistical significance. All statistical analyses were performed using the EZR software package.
Table 1  Patient characteristics

| UPN | HBO therapy | Age | Sex | Diagnosis | Clinical status | PS | HCT-CI | Conditioning regimen | Stem cell source | HLA disparity | GVHD prophylaxis |
|-----|-------------|-----|-----|-----------|-----------------|----|--------|----------------------|-----------------|--------------|-----------------|
| 1   | Yes         | 53  | M   | AML      | CR1             | 1  | 0      | CY + TBI 12 Gy        | R-BM            | Matched      | CsA + sMTX     |
| 2   | Yes         | 32  | F   | ALL      | CR1             | 0  | 0      | CY + ETP + TBI 12 Gy | CB              | Two locus mismatched | CsA + sMTX     |
| 3   | Yes         | 57  | F   | NHL      | CR3             | 1  | 2      | Flu + Bu + TBI 12 Gy | R-PBSC          | One locus mismatched | TAC + sMTX + ATG |
| 4   | Yes         | 50  | M   | MDS non CR | PR             | 0  | 2      | Flu + Bu + TBI 12 Gy | R-PBSC          | Haplo        | TAC + sMTX + PTCy |
| 5   | Yes         | 64  | F   | ATL      | PR              | 1  | 3      | Flu + Bu + TBI 12 Gy | R-PBSC          | Haplo        | TAC + sMTX + PTCy |
| 6   | Yes         | 57  | M   | ALL      | CR1             | 1  | 0      | Flu + Bu + TBI 12 Gy | R-PBSC          | Haplo        | TAC + sMTX + PTCy |
| 7   | Yes         | 45  | F   | ALL      | CR2             | 1  | 3      | CY + ETP + TBI 12 Gy | UR-BM           | Matched      | TAC + sMTX     |
| 8   | Yes         | 33  | M   | AML      | CR2             | 0  | 2      | CA + CY + TBI 12 Gy | CB              | Two locus mismatched | TAC + sMTX     |
| 9   | No          | 47  | M   | NHL      | CR1             | 1  | 2      | Flu + Mel + TBI 14 Gy | UR-BM           | Matched      | CsA + sMTX     |
| 10  | No          | 59  | M   | ATL      | PR              | 1  | 2      | Flu + Mel + TBI 14 Gy | UR-BM           | Matched      | CsA + sMTX     |
| 11  | No          | 22  | M   | AML      | REL1            | 1  | 4      | Flu + Mel + TBI 14 Gy | CB              | Two locus mismatched | CsA + sMTX     |
| 12  | No          | 22  | M   | ALL      | CR1             | 0  | 0      | CY + ETP + TBI 12 Gy | R-BM            | Matched      | CsA + sMTX     |
| 13  | No          | 44  | M   | CML      | CCyR1           | 1  | 1      | CA + CY + TBI 12 Gy | CB              | Two locus mismatched | CsA + MMF      |
| 14  | No          | 31  | M   | HL       | CR1             | 1  | 0      | CA + CY + TBI 12 Gy | UR-BM           | Matched      | CsA + sMTX     |
| 15  | No          | 50  | F   | AML      | CR2             | 1  | 1      | CA + CY + TBI 12 Gy | UR-BM           | Two locus mismatched | TAC + sMTX + ATG |
| 16  | No          | 31  | F   | AML      | CR              | 0  | 0      | CA + CY + TBI 12 Gy | CB              | One locus mismatched | TAC + sMTX     |

UPN unique patient number, *M* male, AML acute myeloid leukemia, Cy cyclophosphamide, ATG antithymocyte globulin, *TBI* total body irradiation, *UR* unrelated, *BM* bone marrow, *FK* tacrolimus, *sMTX* short course of methotrexate, *Flu* fludarabine, ALL acute lymphoblastic leukemia, *Mel* melphalan, CML chronic myelogenous leukemia, *CyCR* cytological complete remission, *F* female, *Haplo* haploidentical transplant, *CB* cord blood, *MDS* myelodysplastic syndrome, *NHL* Non-Hodgkin lymphoma, *ATL* adult T cell leukemia-lymphoma, *PS* performance status. *HCT-CI* hematopoietic cell transplant-comorbidity index.
Results

Development of HC

The 16 patients were diagnosed with virus-associated HC at a median 31 days (range 7–764 days) after allo-HSCT (Table 2). The median time to the onset of HC after allo-HSCT in the HBO(+) patients (median 29 days, range 13–764 days) and HBO(−) patients (median 48 days, range 7–630 days) did not differ to a statistically significant extent. Among the 8 HBO(+) patients, 2 (25%, UPNs 1 and 6) had ADV-HC, while the other 6 (75%, UPNs 2, 3, 4, 5, 7 and 8) had BKV-HC. Among the 8 HBO(−) patients, 2 (25%, UPNs 9 and 10) and 6 (75%, UPNs 11–16) had ADV- and BKV-HC, respectively. The severity of HC was comparable between the HBO(+) (7 had grade II and 1 had grade III) and HBO(−) (7 had grade II and 1 had grade IV) patients.

Three (UPNs 4, 8, and 16) of the 16 patients (19%) had grade I acute aGVHD; one of these patients received corticosteroids for the treatment of aGVHD at the onset of virus-associated HC and the patients responded to corticosteroids well. Five of the 16 patients (31%) had been treated with ganciclovir (GCV) and/or foscarnet (PFA) for the treatment of CMV antigenemia at the time of the diagnosis of virus-associated HC.

HBO therapy for virus-associated HC

Table 3 summarizes HBO and conventional therapies, as well as their outcomes. The median number of HBO therapy sessions was 10 (range 8–12) times and the median

| UPN | Engraftment | Acute GVHD | Steroid use | Onset of HC (d from SCT) | Hematuria (Grade) | Viruria | Viral infections | Antiviral therapy at HC | CR (d from therapy) |
|-----|-------------|------------|-------------|--------------------------|-------------------|--------|-----------------|------------------------|---------------------|
| 1   | d15         | –          | –           | 764                     | II                | ADV    | –               | –                      | 25                  |
| 2   | d20         | –          | –           | 24                      | II                | BKV    | –               | PFA                    | 21                  |
| 3   | d15         | –          | –           | 59                      | II                | BKV    | CMV antigenemia | PFA                    | 13                  |
| 4   | d17         | I          | +           | 38                      | II                | BKV    | –               | –                      | 13                  |
| 5   | d22         | –          | –           | 34                      | II                | BKV    | –               | –                      | 5                   |
| 6   | d18         | –          | –           | 18                      | II                | ADV    | CMV antigenemia | GCV                    | 11                  |
| 7   | d17         | –          | –           | 13                      | II                | BKV    | CMV antigenemia | PFA                    | 22                  |
| 8   | d18         | I          | –           | 21                      | III               | BKV    | –               | –                      | 16                  |
| 9   | d17         | –          | –           | 630                     | II                | ADV    | –               | –                      | 24                  |
| 10  | d17         | –          | –           | 21                      | II                | ADV    | –               | –                      | 17                  |
| 11  | d16         | –          | –           | 22                      | II                | BKV    | HHV-6           | PFA                    | 25                  |
| 12  | d25         | –          | –           | 7                       | II                | BKV    | –               | –                      | 13                  |
| 13  | d19         | –          | –           | 68                      | II                | BKV    | CMV antigenemia | GCV, PFA               | NE                  |
| 14  | d21         | –          | –           | 28                      | IV                | BKV    | –               | Ara-A                  | NE                  |
| 15  | d17         | –          | –           | 96                      | II                | BKV    | CMV antigenemia | PFA, DLI, CDV           | NE                  |
| 16  | d27         | I          | –           | 200                     | II                | BKV    | –               | –                      | 216                 |

SCT stem cell transplantation, EBV Epstein–Barr virus, CMV Cytomegalovirus, GCV ganciclovir, PFA foscarnet, CDV cidofovir, DLI donor lymphocyte infusion, CR complete resolution, GVHD graft-versus-host disease, NE not evaluable

Table 3 Summary of the treatment of patients with virus-associated cystitis

|                      | HBO+ group (n=8) | HBO− group (n=8) | p-value |
|----------------------|------------------|------------------|---------|
| Onset of HC          | 29 (13–764)      | 48 (7–630)       | n.s     |
| Virus                | BKV 6 (75%)      | BKV 6 (75%)      | n.s     |
|                      | ADV 2 (25%)      | ADV 2 (25%)      | n.s     |
| Number of HBO therapy| Median (range)   | 10 (8–12)        | NA      |
| From therapy to CR   | 14.5 (5–25)      | 24 (13–216)      | n.s     |
| Response rate        | 8/8 (100%)       | 5/8 (62.5%)      | n.s     |

HC hemorrhagic cystitis, CR complete resolution, NA not applicable, n.s. not significant
The duration of HBO therapy was 19.5 days (range 10–23 days). The response rate was 100% (8/8) in HBO(+) patients and 62.5% (5/8) in HBO(−) patients. All eight HBO(+) patients achieved a PR in 2–17 (median 6.5) days and a CR in 5–25 (median 14.5) days after the start of HBO therapy. The time from therapy to CR in HBO(+) patients tended to be shorter than that in HBO(−) patients (median 14.5 vs. 24 days), but it was not statistically significant. The urine virus load decreased 2 weeks after the start of HBO therapy in one patient (UPN2), which we previously reported [22].

Of 8 HBO(−) patients, 3 (37.5%, UPNs 13–15) did not achieve a PR or CR and remained symptomatic for 2–6 months.

**Safety and tolerability of treatment**

There were no severe adverse effects due to HBO therapy in any of the 8 HBO(+) patients. One patient (UPN 4) had unilateral serous otitis media after HBO therapy, which was resolved with tympanostomy. Although an ear pain or discomfort and middle ear barotrauma (MEB) [26] are common adverse effects of HBO, none of the other 7 HBO(+) patients developed these complications.

One (UPN 14) of the HBO(−) patients with BKV-HC was complicated by renal dysfunction due to clot retention in the ureters and eventually died of uremia. None of the 8 HBO(+) patients and none of the other 7 HBO(−) patients developed renal functional impairment during the course of HC.

**Transplant outcomes**

All 8 HBO(+) patients survived more than 100 days after HSCT. Two HBO(+) patients (UPNs 1 and 5) died of relapse more than 1 years after HSCT, but there was no transplant-related mortality (TRM). Of 4 HBO(−) patients who died 2–17 months after allo-HSCT, 3 (UPNs 13–15) succumbed to TRM, which was associated with infection and organ failure. The other HBO(−) patient (UPN 11) died of relapse more than 1 years after HSCT. The cumulative incidence of TRM at day 100 after allo-HSCT was significantly higher in HBO(−) patients than in HBO(+) patients (14.2 vs. 0%, $P < 0.05$, Fig. 1).

**Discussion**

This retrospective study revealed several potential benefits of HBO therapy in the treatment of HC after allo-HSCT. HBO therapy produced a higher CR rate (100%) and shortened the time from therapy to CR in comparison to conventional therapies. In addition, the TRM rate at day 100 in HBO(+) patients was lower than that in HBO(−) patients, leading to a higher non-relapse survival rate in HBO(+) patients.

All eight patients completed HBO therapy without severe adverse effects, with success even in patients receiving corticosteroids for the treatment of aGVHD. HBO therapy is, therefore, thought to be feasible option for the treatment of virus-associated HC after allo-HSCT.

Several studies have demonstrated the effectiveness of HBO therapy for BKV-HC [20–23]. A retrospective study from Portugal showed that 15 (94%) of 16 BKV-HC patients treated with HBO therapy achieved a CR after a median of 17 days (range 4–116 days) [20]. In a pediatric cohort of 10 children with BKV-HC, HBO therapy produced a CR in 9 (90%) patients after a median of 15 days (range 10–37 days) [21]. Another retrospective study reported that all 5 adult patients transplanted from matched unrelated donors responded to HBO therapy and achieved a CR after the mean of 13 sessions (range 11–30 sessions). However, none of these studies directly compared the treatment outcomes between patients who received HBO and conventional therapy at a single institution. We showed that the time from therapy to CR in HBO(+) patients was significantly shorter than that in HBO(−) patients. Although the number of patients was limited, our comparative study provided further evidence that HBO therapy is a promising treatment option for patients with HC after allo-HSCT.

To our knowledge, there are no standard treatment guidelines for post-HSCT HC. Intravenous hydration with forced
diuresis is usually conducted; however, this is a supportive treatment that does not show reliable efficacy. The efficacy of CDV against ADV-HC has been demonstrated by a prospective clinical trial [12]; however, the role of CDV in the treatment of BKV-HC was only investigated in retrospective studies [14, 27, 28]. For example, in a report from the European Group for Blood and Marrow Transplantation (EBMT), intravenous or intravesical CDV was administered to 62 patients with BKV-HC [14], and 41 (66%) achieved CR and 8 (13%) achieved a PR. Notably, of the 57 patients who received intravenous CDV treatment, 17 (30%) experienced renal dysfunction. We did not use CDV for the treatment of our patients with HC, with the exception of one patient (UPN15) with severe acute respiratory distress syndrome caused by pneumonia, because CDV has not received approval in Japan. Given the nephrotoxicity of intravenous CDV and the safety profile of HBO therapy, it may be a reasonable approach to start treatment with HBO in the early course of HC, particularly for patients with renal dysfunction.

HBO has been utilized as primary or adjunctive therapy for several medical conditions where tissue damage is triggered by hypoxic injury, due to its stimulatory effects on fibroblast proliferation, angiogenesis, and wound healing [29]. Although the precise pathogenesis of virus-associated HC remains unclear, virus-infected urothelial cells may be associated with the denudation of the damaged mucosa in patients with HC [30]. HBO therapy may protect urothelial cells by stimulating fibroblast proliferation, angiogenesis, and wound healing.

The present study was associated with some limitations. The study population was relatively small and the patients were treated at a single center; thus, there may be some bias in relation to the treatment outcomes. Although the urine BKV load markedly decreased 2 weeks after the start of HBO therapy in UPN2, we could not monitor the change of the viral load in the other 15 patients. The impact of HBO therapy on HC needs to be determined in a prospective study where the viral load is sequentially followed in every sample.

In conclusion, our comparative study provided further evidence that HBO is a feasible option for the treatment of viral HC after allogeneic HSCT.

Acknowledgements We thank the inpatient nursing team and the support staff for the excellent care they provided to our donors, patients, and their families.

Author contributions KH, GA, and SN participated in the design of this analysis. KH, GA, KO, HT, NN, TM, NI, KI, YK, and HY recruited patients to participate in the study. KI and MK performed the qPCR assays. TN and MT performed the HBO therapy. KH and GA analyzed the data. KH, GA, and SN wrote the manuscript. All the authors critically reviewed the manuscript content and agreed with the submission of the final manuscript. KH and GA contributed equally to this work.

Declarations

Conflict of interest The authors declare no conflicts of interest associated with the present study.

References

1. Miyamura K, Takeyama K, Kojima S, Minami S, Matsuyama K, Morishima Y, et al. Hemorrhagic cystitis associated with urinary excretion of adenovirus type 11 following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1989;4(5):533–5.
2. Akiyama H, Kurosu T, Sakashita C, Inoue T, Mori S, Ohashi K, et al. Adenovirus is a key pathogen in hemorrhagic cystitis associated with bone marrow transplantation. Clin Infect Dis. 2001;32(9):1325–30.
3. Asano Y, Kanda Y, Ogawa N, Sakata-Yanagimoto M, Nakagawa M, Kawazu M, et al. Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32(12):1175–9.
4. Yamamoto R, Kusumi E, Kami M, Yuji K, Hamaki T, Saito A, et al. Late hemorrhagic cystitis after reduced-intensity hematopoietic stem cell transplantation (RIST). Bone Marrow Transplant. 2003;32(11):1089–95.
5. Nakazawa Y, Saito S, Yangasiwara R, Suzuki T, Ito T, Ishida F, et al. Recipient seropositivity for adenovirus type 11 (AdV11) is a highly predictive factor for the development of AdV11-induced hemorrhagic cystitis after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48(5):737–9.
6. Mori Y, Miyamoto T, Kato K, Kamezaki K, Kuriyama T, Oku S, et al. Different risk factors related to adenovirus- or BK virus-associated hemorrhagic cystitis following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(3):458–65.
7. Arai Y, Maeda T, Sugiuira H, Matsui H, Jo T, Ueda T, et al. Risk factors for and prognosis of hemorrhagic cystitis after allogeneic stem cell transplantation: retrospective analysis in a single institution. Hematology. 2012;17(4):207–14.
8. Hayden RT, Gu Z, Liu W, Lovins R, Kasow K, Woodard P, et al. Risk factors for hemorrhagic cystitis in pediatric allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2015;17(2):234–41.
9. Lunde LE, Dasaraju S, Cao Q, Cohn CS, Reding M, Bejanyan N, et al. Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. Bone Marrow Transplant. 2015;50(11):1432–7.
10. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7(7):388–94.
11. Ljungman P, Ribaud P, Eyrich M, Mattthes-Martin S, Einsele H, Bleakley M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2003;31(6):481–6.
12. Nagafuji K, Aoki K, Hennan H, Kato K, Miyamoto T, Eto T, et al. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2004;34(10):909–14.
13. Yusuf U, Hale GA, Carr J, Gu Z, Benaim E, Woodard P, et al. Cidofovir for the treatment of adenoviral infection in pediatric
115

Effectiveness of hyperbaric oxygen therapy for virus-associated hemorrhagic cystitis after...